Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients
Referencias
Additional references
Ashraf MS, Brady J, Breatnach F, Deasy PF, O'Meara A. Ifosfamide nephrotoxicity in paediatric cancer patients. European Journal of Pediatrics 1994;153:90‐94.
Carli M, Passone E, Perilongo G, Bisogno G. Ifosfamide in pediatric solid tumors. Oncology 2003;65 Suppl 2:99‐104.
Higgins J, Green S (eds.). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. http://www.cochrane.org/resources/handbook/hbook.htm (accessed 15th December 2005)2005.
Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al. Intergroup rhabdomyosarcoma study‐IV: results for patients with nonmetastatic disease. Journal of Clinical Oncology 2001;19:3091‐3102.
Durkan A, Hodson EM, Willis NS, Craig JC. Non‐corticosteroid treatment for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2005, Issue 2.
Fawaz O, Ridola V, Schmitt C, Gentet JC, Aubier F, Orbach D, et al. Ifosfamide vs. cyclophosphamide: Long term gonadal effects in male survivors of childhood cancer. Sarcoma. 2005; Vol. 9:61.
German Childhood Cancer Registry: Annual Report 2004. http://www.kinderkrebsregister.de/texte04pdf/6_22.pdf (accessed 15th December 2005).
German Childhood Cancer Registry: Annual Report 2004 Appendix. http://www.kinderkrebsregister.de/texte04pdf/taba1te2.pdf (accessed 15th December 2005).
Howell SJ, Shalet SM. Testicular function following chemotherapy. Human Reproduction Update 2001;7:363‐369.
Kasper B, Ho AD, Egerer G. Is there an indication for high‐dose chemotherapy in the treatment of bone and soft‐tissue sarcoma?. Oncology 2005;68:115‐121.
Koscielniak E, Harms D, Henze G, Jürgens H, Gadner H, Herbst M, et al. Results of Treatment for Soft Tissue Sarcoma in Childhood and Adolescence: A Final Report of the German Cooperative Soft Tissue Sarcoma Study CWS‐86. Journal of Clinical Oncology 1999;17:3706‐3719.
Lai KN, Tang SC, Mok CC. Treatment for lupus nephritis: a revisit. Nephrology (Carlton) 2005;10:180‐188.
Nicolao P, Giometto B. Neurological toxicity of ifosfamide. Oncology 2003;65 Suppl 2:11‐16.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐2834.
Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. Journal of Clinical Oncology 2001;19:1818‐1829.
Rossi R, Kleta R, Ehrich JH. Renal involvement in children with malignancies. Pediatric Nephrology 1999;13:153‐162.
Ruymann FB, Vietti T, Gehan E, Wiener E, Wharam M, Newton WA, et al. Cyclophosphamide dose escalation in combination with vincristine and actinomycin‐D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response. Journal of Pediatric Hematology and Oncology 1995;17:331‐337.
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408‐412.
Shaw PJ, Eden T. Ifosfamide in paediatric oncology: tried but not tested?. Lancet 1990;335:1022‐1023.
Simbre VC, Duffy SA, Dadlani GH, Miller TL, Lipshultz SE. Cardiotoxicity of cancer chemotherapy: implications for children. Paediatric Drugs 2005;7:187‐202.
Skinner R. Chronic ifosfamide nephrotoxicity in children. Medical and Pediatric Oncology 2003;41:190‐197.
Spunt SL, Smith LM, Ruymann FB, Qualman SJ, Donaldson SS, Rodeberg DA, et al. Cyclophosphamide dose intensification during induction therapy for intermediate‐risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group. Clinical Cancer Research 2004;10:6072‐6079.
Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology‐‐SIOP Malignant Mesenchymal Tumor 89. Journal of Clinical Oncology 2005;23:2618‐2628.
Stöhr W, Patzer L, Paulides M, Kremers A, Beck JD, Langer T, et al. Growth impairment after ifosfamide‐induced nephrotoxicity in children. Pediatric Blood and Cancer 2006;June 5:epub ahead of print.
Umapathi T, Hughes RA, Nobile‐Orazio E, Leger JM. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database of Systematic Reviews 2005, Issue 3.
Verweij J, Mouridsen HT, Nielsen OS, Woll PJ, Somers R, van Oosterom AT, et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Critical Reviews in Oncology/Hematology 1995;20:193‐201.
Weller F, Huppertz HI. The treatment of juvenile rheumatism: pharmacotherapy [Die Behandlung des kindlichen Rheumas: Pharmakotherapie]. Zeitschrift fur Rheumatologie 2005;64:308‐316.
Zhang J, Tian Q, Chan SY, Duan W, Zhou S. Insights into oxazaphosphorine resistance and possible approaches to its circumvention. Drug Resistance Updates 2005;8:271‐297.
